Search

Dinshaw J. Patel, a Member in Sloan Kettering Institute's Structural Biology Program and incumbent of the Abby Rockefeller Mauzé Chair in Experimental Therapeutics, was elected to the National Academy of Sciences at its 146th annual meeting in April.

… Wednesday, July 1, 2009 Summary Dinshaw J. Patel, a Member in Sloan Kettering Institute’s Structural Biology Program and incumbent of the Abby Rockefeller Mauzé Chair in Experimental Therapeutics, was elected to the National Academy of Sciences at its 146th annual meeting in April. Dinshaw J. Patel ,

MSK researchers discover a possible reason why people with kidney cancer respond better to treatments such as immunotherapy if they are obese.

… Friday, December 20, 2019 Summary Obesity increases the risk of developing kidney cancer . However, obese people seem to do better after treatment compared with people of normal weight. MSK researchers have discovered that fat surrounding kidney tumors may play a key role in the effectiveness of kidney

MSK 斯隆的研究人员发现了肾癌患者在肥胖的情况下对免疫疗法等治疗反应更好的一个可能原因。MSK 斯隆的研究人员发现了肾癌患者在肥胖的情况下对免疫疗法等治疗反应更好的一个可能原因。

… Friday, December 20, 2019 总结 肥胖会增加患 肾癌 的风险。然而，与正常体重的人相比，肥胖的人接受治疗的效果似乎更好。MSK 斯隆的研究人员发现，肾脏肿瘤周围的脂肪可能对肾癌治疗的有效性起关键作用。 长期以来，肾癌专家一直对这种疾病与肥胖之间的奇怪关系感到困惑。尽管肥胖人群患癌症的风险增加，但他们比非肥胖人群在疾病中存活的几率高。 纪念斯隆凯特琳癌症中心的研究人员多年来一直在研究这一被称为“肥胖悖论”的现象。2014 年，由流行病学家 Helena Furberg 和泌尿肿瘤外科医生 Ari Hakimi 领导的一个研究小组发现，由于肥胖人群的一个促癌基因活性较低， 其肿瘤的生长速度可能会减慢

African American patients with colorectal cancer are less likely to have tumors that respond well to newer treatments such as targeted therapy and immunotherapy.

… Monday, April 17, 2023 The disparities are disturbing: Black men and women are more likely to get colorectal cancer than any other racial group in the United States. They also are 40% more likely to die from it than other racial groups. There are many possible explanations , including differences in

It can be hard to understand all the various radiation therapy options for prostate cancer. Here, we explain.

… Wednesday, July 2, 2025 The latest treatments for  prostate cancer have become more effective, convenient, and personalized for patients than ever before. Among the most powerful tools is  radiation therapy , which can be delivered in multiple ways to target prostate cancer with precision, while minimizing

Puede ser difícil comprender las diversas opciones de radioterapia utilizadas para tratar el cáncer de próstata. Aquí las explicamos.

… Wednesday, July 2, 2025 Cuando se trata de tratamiento para el cáncer de próstata , actualmente los hombres cuentan con muchas opciones que han mejorado la prevención de la enfermedad. Un tratamiento eficaz es la radioterapia, sola o combinada con otros tratamientos como la terapia hormonal o la cirugía

Scientists at Memorial Sloan Kettering have pieced together the biochemical mechanism by which the tuberculosis bacterium sneaks past our immune defenses.

… Tuesday, June 15, 2021 Tuberculosis (TB) isn’t very common in the US, but worldwide it causes an immense amount of suffering. “It’s a persistent, decades-long pandemic,” says Michael Glickman , an infectious disease specialist at Memorial Sloan Kettering and member of the Immunology Program in the Sloan

Read about a powerful research model developed by MSK researchers to learn how the most common type of prostate cancer changes into a deadly form.

… Wednesday, October 16, 2024 A leading scientist whose discoveries about prostate cancer led to lifesaving treatments is now shedding light on an emerging and deadlier form of the disease: neuroendocrine prostate cancer (NEPC). Most prostate cancers are classified as adenocarcinomas, which rely on a protein

MSK physician-scientist Prasad Adusumilli is focused on developing more-effective immunotherapy approaches for treating tumors in the chest.

… Tuesday, October 11, 2016 Summary MSK physician-scientist Prasad Adusumilli is focused on developing more-effective immunotherapy approaches for treating tumors in the chest. This magnified image shows immune cells, in blue, attacking and killing mesothelioma cells, in magenta. (Cells have been artificially

During the June 8 edition of “MSK Science Spotlight,” radiochemist Jason Lewis, PhD, will share his perspectives on “Defying the Limitations of Antibodies for Imaging and Endoradiotherapy.”

… Monday, June 8, 2020 During the June 8 edition of “ MSK Science Spotlight ,” radiochemist Jason Lewis , PhD, will share his perspectives on “Defying the Limitations of Antibodies for Imaging and Endoradiotherapy.” Dr. Lewis is Vice Chair for Research, Department of Radiology and Chief, Radiochemistry